Pharmaceutical Executive Daily
New research suggests Ozempic may reduce biological age.
In today's Pharmaceutical Executive Daily, we cover the FDA approval of Bayer's Lynkuet for menopausal hot flashes and Novartis' $12 billion merger agreement to acquire Avidity Biosciences.
FDA Approval of Lynkuet
The FDA has approved Bayer's Lynkuet, also known as elinzanetant, as the first dual neurokinin 1 and 3 receptor antagonist for the treatment of moderate to severe vasomotor symptoms associated with menopause.
- Based on Phase III OASIS trial data showing significant reductions in hot flash frequency and severity.
- Provides an important new therapeutic alternative for patients seeking relief from menopausal symptoms without estrogen exposure.
New research suggests Ozempic may reduce biological age.
Author's summary: Ozempic may reduce biological age, Lynkuet approved.
More News
- Full steam ahead for good causes at train station's big birthday bash
- Tunbridge Wells gridlocked as residents queue for fresh water after five-day outage
- Canada's Air Transat to suspend flights
- Benin coup attempt foiled by loyalist troops, interior minister says
- Breaking: Loyalist troops foil coup attempt in Benin
- Another Coup In Africa, Soldiers Appear On State TV To Announce Takeover
- Flight Booking, Cheap Flights, Air Tickets at Lowest Fare
- Benin: the government declares coup attempt has been 'foiled'
- Heavy rain gridlocks KL traffic
- Attempted coup d'état in Benin